Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia

被引：45

作者：

Ghannam, Jack ^{[1
]}

Dillon, Laura W. ^{[1
]}

Hourigan, Christopher S. ^{[1
]}

机构：

[1] NHLBI, Lab Myeloid Malignancies, NIH, Bldg 10 CRC,Room 5-5130,10 Ctr Dr, Bethesda, MD 20892 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 188卷 / 01期

基金：

美国国家卫生研究院;

关键词：

minimal residual disease; acute myeloid leukaemia; genetics; measurable residual disease; mutation detection; myeloid leukaemia; CLONAL HEMATOPOIESIS; DNMT3A MUTATIONS; RELAPSE; AML; GUIDELINES; DIAGNOSIS; FLT3-ITD; REVEALS; ASSAY;

D O I：

10.1111/bjh.16362

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter- and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next-generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.

引用

页码：77 / 85

页数：9

共 64 条

[21] Measurable residual disease testing in acute myeloid leukaemia [J].

Hourigan, C. S. ;

Gale, R. P. ;

Gormley, N. J. ;

Ossenkoppele, G. J. ;

Walter, R. B. .

LEUKEMIA, 2017, 31 (07) :1482-1490

[22]

Illumina, 2018, EFF IND MIS MULT DOW

[23] Oxidative Stress Is Not a Major Contributor to Somatic Mitochondrial DNA Mutations [J].

Itsara, Leslie S. ;

Kennedy, Scott R. ;

Fox, Edward J. ;

Yu, Selina ;

Hewitt, Joshua J. ;

Sanchez-Contreras, Monica ;

Cardozo-Pelaez, Fernando ;

Pallanck, Leo J. .

PLOS GENETICS, 2014, 10 (02)

[24] Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists [J].

Jennings, Lawrence J. ;

Arcila, Maria E. ;

Corless, Christopher ;

Kamel-Reid, Suzanne ;

Lubin, Ira M. ;

Pfeifer, John ;

Temple-Smolkin, Robyn L. ;

Voelkerding, Karl V. ;

Nikiforova, Marina N. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (03) :341-365

[25] Molecular Minimal Residual Disease in Acute Myeloid Leukemia [J].

Jongen-Lavrencic, M. ;

Grob, T. ;

Hanekamp, D. ;

Kavelaars, F. G. ;

al Hinai, A. ;

Zeilemaker, A. ;

Erpelinck-Verschueren, C. A. J. ;

Gradowska, P. L. ;

Meijer, R. ;

Cloos, J. ;

Biemond, B. J. ;

Graux, C. ;

Kooy, M. van Marwijk ;

Manz, M. G. ;

Pabst, T. ;

Passweg, J. R. ;

Havelange, V. ;

Ossenkoppele, G. J. ;

Sanders, M. A. ;

Schuurhuis, G. J. ;

Lowenberg, B. ;

Valk, P. J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1189-1199

[26] Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse [J].

Kim, TaeHyung ;

Moon, Joon Ho ;

Ahn, Jae-Sook ;

Kim, Yeo-Kyeoung ;

Lee, Seung-Shin ;

Ahn, Seo-Yeon ;

Jung, Sung-Hoon ;

Yang, Deok-Hwan ;

Lee, Je-Jung ;

Choi, Seung Hyun ;

Lee, Ja-yeon ;

Tyndel, Marc S. ;

Shin, Myung-Geun ;

Lee, Yoo Jin ;

Sohn, Sang Kyun ;

Park, Seong-Kyu ;

Zhang, Zhaolei ;

Kim, Hyeoung-Joon ;

Kim, Dennis Dong Hwan .

BLOOD, 2018, 132 (15) :1604-1613

[27] Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia [J].

Klco, Jeffery M. ;

Miller, Christopher A. ;

Griffith, Malachi ;

Petti, Allegra ;

Spencer, David H. ;

Ketkar-Kulkarni, Shamika ;

Wartman, Lukas D. ;

Christopher, Matthew ;

Lamprecht, Tamara L. ;

Helton, Nicole M. ;

Duncavage, Eric J. ;

Payton, Jacqueline E. ;

Baty, Jack ;

Heath, Sharon E. ;

Griffith, Obi L. ;

Shen, Dong ;

Hundal, Jasreet ;

Chang, Gue Su ;

Fulton, Robert ;

O'Laughlin, Michelle ;

Fronick, Catrina ;

Magrini, Vincent ;

Demeter, Ryan T. ;

Larson, David E. ;

Kulkarni, Shashikant ;

Ozenberger, Bradley A. ;

Welch, John S. ;

Walter, Matthew J. ;

Graubert, Timothy A. ;

Westervelt, Peter ;

Radich, Jerald P. ;

Link, Daniel C. ;

Mardis, Elaine R. ;

DiPersio, John F. ;

Wilson, Richard K. ;

Ley, Timothy J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (08) :811-822

[28] Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease [J].

Kohlmann, A. ;

Nadarajah, N. ;

Alpermann, T. ;

Grossmann, V. ;

Schindela, S. ;

Dicker, F. ;

Roller, A. ;

Kern, W. ;

Haferlach, C. ;

Schnittger, S. ;

Haferlach, T. .

LEUKEMIA, 2014, 28 (01) :129-137

[29] Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data [J].

Kroigard, Anne Bruun ;

Thomassen, Mads ;

Laenkholm, Anne-Vibeke ;

Kruse, Torben A. ;

Larsen, Martin Jakob .

PLOS ONE, 2016, 11 (03)

[30] A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations [J].

Levis, Mark J. ;

Perl, Alexander E. ;

Altman, Jessica K. ;

Gocke, Christopher D. ;

Bahceci, Erkut ;

Hill, Jason ;

Liu, Chaofeng ;

Xie, Zhiyi ;

Carson, Andrew R. ;

McClain, Valerie ;

Stenzel, Timothy T. ;

Miller, Jeffrey E. .

BLOOD ADVANCES, 2018, 2 (08) :825-831

← 1 2 3 4 5 6 7 →